Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

NIST, DOD, Intelligence Agencies Join Forces To Secure US Cyber Infrastructure
The National Institute of Standards and Technology (NIST), in partnership with the Department of Defense (DOD), the Intelligence Community (IC), and the Committee on National Security Systems (CNSS), has released the first installment of a three-year effort to build a unified information security framework for the entire federal government. Historically, information systems at civilian agencies have operated under different security controls than military and intelligence information systems. This installment is titled NIST Special Publication 800-53, Revision 3, Recommended Security Controls for Federal Information Systems and Organizations.
generic viagra online
U.N. Program Has Little Effect In Reducing Deaths Among Children In Bangladesh, Study Finds
"The U.N. unveiled a multimillion dollar strategy a dozen years ago to save children worldwide, but a new [Lancet] study has found the program had surprisingly little effect in Bangladesh, one of the world"s poorest countries," the Associated Press reports. Since 1997, when the WHO and UNICEF launched the Integrated Management of Childhood Illness (IMCI) Program to help reduce the numbers of deaths in children under age 5 from diarrhea, pneumonia, measles and malnutrition, more than 100 countries have adopted the program, drawing upon "millions" in aid, according to the news service.
plastic surgery before after
News of the day
MS Society Pleased With Government Recognition Of Crisis In Social Care
The government"s Green Paper "Shaping the Future of Care Together" has been welcomed by the MS Society as the radical step necessary to address the crisis in social care.
Mental Health

Provectus Pharmaceuticals To Offer Compassionate Use Of PV-10 For Non-Visceral Indications In Cancer Patients

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has begun a compassionate use program for PV-10 and has made the agent, which is in development as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients. Initially, the compassionate use program will only be available for cancer indications that do not involve visceral organs and are not subject to enrollment in ongoing clinical trials. These indications include certain breast cancers, basal cell carcinoma, squamous cell carcinoma, certain head and neck cancers and melanoma. Provectus has begun its compassionate program for PV-10 in certain Australian "Centers of Excellence," including Sydney, Brisbane and Adelaide, and will expand it to the United States in coming months. The Australian program is under the guidelines of the Therapeutic Goods Administration"s Special Access Scheme, while the U.S. program is expected to be under the FDA"s regulations covering Treatment Use of an investigational new drug. Interested parties are encouraged to visit Provectus" website, http://www.pvct.com, where details on the compassionate use program and additional information will be posted in the near future. Compassionate use programs provide experimental therapeutics to patients prior to final FDA approval. Dr. Kelly McMasters, a preeminent physician and investigator who is a member of Provectus" Board of Directors and head of its Scientific Advisory Board, will advise the Company on candidates for the program who might be safely helped by PV-10. "The potential for PV-10 to successfully treat metastatic melanoma, which has already been shown in humans, warrants its further use for melanoma and for other life-threatening scenarios on a compassionate use basis," said Dr. McMasters. Provectus is currently completing its Phase 2 clinical trial of PV-10 as a therapy for metastatic melanoma and has completed Phase 1 clinical testing of PV-10 for the treatment of recurrent breast carcinoma. "We decided to initiate this program as we have had a continuing large number of requests by physicians and patients to make PV-10 available on a compassionate basis," said Craig Dees, Ph.D., CEO of Provectus. "Preliminary analysis of interim Phase 2 results from our melanoma clinical trial suggests that we can safely provide PV-10 for treatment of selected cancer patients, and that the agent has potential to benefit some of these patients. Knowing this information, we believe the ethical choice is to make the drug available on a compassionate use basis." Provectus Pharmaceuticals, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009